Sanofi to trim $170M in annual costs; Novartis' Gilenya hits relapse study target;

@FiercePharma: That $2B to $3B deal size is Big Pharma's sweet spot: Novartis, Roche and now Sanofi say so. Story | Follow @FiercePharma

> Sanofi ($SNY) CEO Christopher Viehbacher told The Boston Globe that the company will trim $170 million in annual costs as it absorbs Genzyme, the rare-disease specialist it bought last year. More

> Novartis ($NVS) said its multiple sclerosis pill Gilenya hit its target in a late-stage trial testing its ability to stave off a relapse in symptoms, with Gilenya patients 48% less likely to relapse than placebo patients. News

> Andrew Lansley, CEO of the U.K. cost-effectiveness watchdog NICE, pledged to require all National Health Service trusts to provide agency-approved drugs to patients who need them, ending so-called "postcode prescribing." Report

> FDA received applications for generic versions of three HIV-fighting drugs: Merck's ($MRK) Isentress, GlaxoSmithKline's ($GSK) Epivir and Bayer's Beyaz. More

> A new strain of tuberculosis that's resistant to all drugs used to fight the disease has emerged in India, local media reports. Article

Biotech News

@FierceBiotech: CRO consolidation to slow in 2012, Icon CEO says. More | Follow @FierceBiotech

@JohnCFierce: It's good to be the CEO, says BMS chief Lamberto Andreotti at #JPM12. Give him his due, he earned it. Story | Follow @JohnCFierce

@MaureenFierce: Researchers develop tech to detect inherited MPS disorders. Article | Follow @MaureenFierce

@RyanMFierce: AstraZeneca taps IMS Health to mine outcomes data, electronic health records and to develop analysis platform. News | Follow @RyanMFierce

@MarkHFierce: It seems that nanotech delivery advances are getting serious already in 2012. | Follow @MarkHFierce

> Early-stage biotech investor Flagship launches $270M fund. Article

> Sanofi deal strategy will shun hep C in global hunt for new 'pearls.' More

> Actelion braces for looming pivotal data on blockbuster macitentan program. Story

> Bristol CEO touts successful biopharma blitz after big hep C play. News

Medical Device News

> Ishrak: Medtronic has eyes on overseas acquisitions. Item

> Ventana, Pfizer, CST collaborate on NSCLC companion diagnostic. Article

> Medical imaging company NeuroLogica grabs $12M in funding. Story

> Active Implants rakes in $10M in financing round. News

> Olympus brings suit against current, former execs over accounting scandal. More

Drug Delivery News

> Nanotech penetrates prostate cancer cells armed with chemo drugs. Story

> Endo grabs BDSI's drug film chronic pain treatment through global license. Article

> Novel nanoparticles penetrate fruit flies' brains; people's may be next. More

> Civitas' inhaled L-dopa Parkinson's treatment passes Phase I. News

Biomarkers News

> Early blood test could predict baby's sex. News

> Researchers find new lung cancer biomarkers. More

> As genome sequences get cheaper, is more always better? Article

> Immune biomarker could link to autism. Story

And Finally... Psoriasis sufferers may be at a greater risk of blocked arteries, a new study finds. Report

Suggested Articles

Besides paying $729 million to settle notorious kickback allegations, Novartis has promised to put strict restrictions on its future speaker programs.

Pharma companies including Pfizer and Novartis paused advertising on Facebook for July to protest hate and disinformation on the platform.

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.